Literature DB >> 18187534

Cocaine/crack cocaine consumption, treatment demand, seizures, related offences, prices, average purity levels and deaths in the UK (1990 - 2004).

Fabrizio Schifano1, John Corkery.   

Abstract

A recent trend of escalating use of cocaine/crack cocaine was observed in the UK. The number of mentions on death certificates; last year use of cocaine; treatment demand, number of drug offenders, seizures, prices and average purity levels were the indicators used for this descriptive and correlational study. Figures (1990-2004) were taken from official UK sources. A total of 1022 cocaine/crack cocaine death mentions (i.e. deaths from any cause where the presence of cocaine/crack cocaine was also detected) were identified, with cocaine/crack cocaine being the sole drug mentioned in 36% of cases. The number of cocaine/crack cocaine death mentions showed a year-on-year increase and correlated positively with the following cocaine (powder) figures: last year use (p < 0.001); number of offenders (p < 0.001) and number of seizures (p < 0.001), but correlated negatively with price (p < 0.001). Furthermore, the number of cocaine/crack cocaine death mentions correlated positively with the number of crack offenders (p < 0.001) and seizures (p < 0.001), but correlated negatively with both crack purity ( p < 0.001) and price (p < 0.05). With conditions of increasing drug availability having been met in the UK, decrease in cocaine prices were associated with higher consumption levels and this, in turn, contributed to the increase in number of cocaine-related fatalities. There are limitations with the information collected, since no distinction is usually made on medical death certificates between cocaine and crack cocaine. The present study being an ecological one, it proved difficult to address the role of confounding variables that may well explain some of the associations observed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18187534     DOI: 10.1177/0269881107079170

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  6 in total

1.  Dietary restriction mitigates cocaine-induced alterations of olfactory bulb cellular plasticity and gene expression, and behavior.

Authors:  Xiangru Xu; Mohamed R Mughal; F Scott Hall; Maria T G Perona; Paul J Pistell; Justin D Lathia; Srinivasulu Chigurupati; Kevin G Becker; Bruce Ladenheim; Laura E Niklason; George R Uhl; Jean Lud Cadet; Mark P Mattson
Journal:  J Neurochem       Date:  2010-04-29       Impact factor: 5.372

2.  Mephedrone ("bath salt") pharmacology: insights from invertebrates.

Authors:  L Ramoz; S Lodi; P Bhatt; A B Reitz; C Tallarida; R J Tallarida; R B Raffa; S M Rawls
Journal:  Neuroscience       Date:  2012-01-20       Impact factor: 3.590

3.  Anhydroecgonine Methyl Ester (AEME), a Product of Cocaine Pyrolysis, Impairs Spatial Working Memory and Induces Striatal Oxidative Stress in Rats.

Authors:  Elisa Fraga Gomes; Ingryd Fortes Souza Lipaus; Cleciane Waldetário Martins; Andrezza Menezes Araújo; Josidéia Barreto Mendonça; Fabrício Souza Pelição; Evandro Carlos Lebarch; Lívia Carla de Melo Rodrigues; Ester Miyuki Nakamura-Palacios
Journal:  Neurotox Res       Date:  2017-09-15       Impact factor: 3.911

4.  Mephedrone ('bath salt') elicits conditioned place preference and dopamine-sensitive motor activation.

Authors:  Renata Lisek; Wei Xu; Ekaterina Yuvasheva; Yi-Ting Chiu; Allen B Reitz; Lee-Yuan Liu-Chen; Scott M Rawls
Journal:  Drug Alcohol Depend       Date:  2012-05-29       Impact factor: 4.492

5.  Estimation of cocaine consumption in the community: a critical comparison of the results from three complimentary techniques.

Authors:  Malcolm J Reid; Katherine H Langford; Merete Grung; Hallvard Gjerde; Ellen J Amundsen; Jorg Morland; Kevin V Thomas
Journal:  BMJ Open       Date:  2012-11-08       Impact factor: 2.692

6.  The nature of methadone diversion in England: a Merseyside case study.

Authors:  Paul Duffy; Helen Baldwin
Journal:  Harm Reduct J       Date:  2012-01-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.